uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
Show others and affiliations
2012 (English)In: Stem Cells, ISSN 1066-5099, Vol. 30, no 7, 1565-1574 p.Article in journal (Refereed) Published
Abstract [en]

Multipotent mesenchymal stromal cells (MSCs) are tested in numerous clinical trials. Questions have been raised concerning fate and function of these therapeutic cells after systemic infusion. We therefore asked whether culture-expanded human MSCs elicit an innate immune attack, termed instant blood-mediated inflammatory reaction (IBMIR), which has previously been shown to compromise the survival and function of systemically infused islet cells and hepatocytes. We found that MSCs expressed hemostatic regulators similar to those produced by endothelial cells but displayed higher amounts of prothrombotic tissue/stromal factors on their surface, which triggered the IBMIR after blood exposure, as characterized by formation of blood activation markers. This process was dependent on the cell dose, the choice of MSC donor, and particularly the cell-passage number. Short-term expanded MSCs triggered only weak blood responses in vitro, whereas extended culture and coculture with activated lymphocytes increased their prothrombotic properties. After systemic infusion to patients, we found increased formation of blood activation markers, but no formation of hyperfibrinolysis marker D-dimer or acute-phase reactants with the currently applied dose of 1.0-3.0 x 10(6) cells per kilogram. Culture-expanded MSCs trigger the IBMIR in vitro and in vivo. Induction of IBMIR is dose-dependent and increases after prolonged ex vivo expansion. Currently applied doses of low-passage clinical-grade MSCs elicit only minor systemic effects, but higher cell doses and particularly higher passage cells should be handled with care. This deleterious reaction can compromise the survival, engraftment, and function of these therapeutic cells. 

Place, publisher, year, edition, pages
2012. Vol. 30, no 7, 1565-1574 p.
Keyword [en]
Mesenchymal stromal cell, Endothelial cell, Cellular therapy, Thrombosis
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-177583DOI: 10.1002/stem.1111ISI: 000305477000024OAI: oai:DiVA.org:uu-177583DiVA: diva2:541234
Available from: 2012-07-16 Created: 2012-07-16 Last updated: 2013-08-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Rasmusson-Duprez, IdaFunke, LillemorMagnusson, Peetra U.Teramura, YujiNilsson-Ekdahl, KristinaKorsgren, OlleNilsson, Bo
By organisation
Clinical ImmunologyDepartment of Immunology, Genetics and Pathology
In the same journal
Stem Cells
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 243 hits
ReferencesLink to record
Permanent link

Direct link